a2sp Ltd, Warwick, UK
a2sp Ltd, are a technology spin-out from the Department of Chemistry at the University of Warwick. a2sp have developed Magic TagŪ Immobilisation Technology, a suite of 5 photo-activated chemistries that can be used to optimize the bio-orientation of small- and macro-molecules when immobilized on solid phases such as microtitre plates, magnetic beads, gold film etc.
Magic TagŪ Immobilisation Technology can be used to:
- Enable chemical genomics approaches to drug discovery and drug reprofiling
- Rapidly identify both primary and secondary drug-protein interactions
- Immobilise small- and macro-molecules for drug screening, protein kinetic measurement and other applications
Prolysis Ltd, Oxford, UK
Prolysis is a development stage biotech with a portfolio of small molecule antibiotics targeting Gyrase B and the newly validated bacterial target FtsZ. In addition to the potential for in-licensing, out-licensing and collaborative development opportunities, Prolysis is interested in exploring discovery collaborations with partners based on Prolysis' highly successful discovery engine. This discovery engine combines innovative approaches to rational drug design, in-silco discovery and patented screening and confirmatory assays based on the work of Prof. Jeff Errington, now the Director of the Institure of Cell and Molecular Biosciences at the University of Newcastle.
BioAgency/Novologix
BioAgency and their subsidiary Novologix have discovered and validated a novel bacterial target involved in the assembly of the bacterial cytoskeleton. The target is ubiquitous and highly conserved in G+ve and G-ve bactera.
In addition a solution phase screening assay has been developed and validated using a small combinatorial library from which novel structures with bactericidal activity have been discovered. BioAgency/Novologix are interested in licensing the target and screening assay for discovery of novel antibiotics.
|
